Related Experiment Video
Updated: May 26, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Next-generation sequencing and its application in acute myeloid leukemia and myelodysplastic syndrome]
Shu-Cheng Gu1, Chun-Kang Chang
1Department of Hematology, Shanghai Jiaotong University, Shanghai, China.
Abstract:
The next-generation sequencing (NGS), as the most practical and reliable method, has replaced the classical Sanger sequencing to help scientists to discover the genetics secrets of human tumor diseases. With the technique development, the whole genome sequencing will be no longer out of reach. Recently, some scientists used the NGS in the research of hematological malignancies and pushed the progress of the whole genome sequencing in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) actively in order to find out the pathogenesis of some hematological malignancies. The NGS and the application of the whole genome sequencing, the exome sequencing, the transcriptome sequencing in AML and MDS are reviewed in this article.
